 4D pharma PLC said results from a phase II evaluation of its key irritable bowel treatment LBP Blautix have appeared in a peer-reviewed scientific publication. The article in Alimentary Pharmacology Therapeutics took a deeper dive into the already revealed finding that the drug has an impact on the symptoms of the two separate IBS cohorts those with constipation and those with diarrhoea. 